Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Recursion Pharmaceuticals, Inc., Viridian Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Recursion Pharmaceuticals, Inc., Viridian Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Recursion Pharmaceuticals, Inc., Viridian Therapeutics and Inc.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Latest Biotechnology and Recursion Pharmaceuticals, Inc., Viridian Therapeutics, Inc. Stock News

As of December 2, 2025, Recursion Pharmaceuticals, Inc. had a $2.3 billion market capitalization, compared to the Biotechnology median of $200.6 million. Recursion Pharmaceuticals, Inc.’s stock is NA in 2025, NA in the previous five trading days and down 25.98% in the past year.

Currently, Recursion Pharmaceuticals, Inc. does not have a price-earnings ratio. Recursion Pharmaceuticals, Inc.’s trailing 12-month revenue is $43.7 million with a % net profit margin. Year-over-year quarterly sales growth most recently was -80.1%. Analysts expect adjusted earnings to reach $-1.606 per share for the current fiscal year. Recursion Pharmaceuticals, Inc. does not currently pay a dividend.

Currently, Viridian Therapeutics, Inc. does not have a price-earnings ratio. Viridian Therapeutics, Inc.’s trailing 12-month revenue is $70.8 million with a -426.6% net profit margin. As of December 2, 2025, Viridian Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-3.532 per share for the current fiscal year. Viridian Therapeutics, Inc. does not currently pay a dividend.

How We Compare Recursion Pharmaceuticals, Inc., Viridian Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Recursion Pharmaceuticals, Inc., Viridian Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Recursion Pharmaceuticals, Inc., Viridian Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Recursion Pharmaceuticals, Inc.	RXRX	D
Viridian Therapeutics, Inc.	VRDN	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Recursion Pharmaceuticals, Inc. has a Growth Score of 28, which is Weak. Viridian Therapeutics, Inc. has a Growth Score of 1, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Recursion Pharmaceuticals, Inc., Viridian Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Recursion Pharmaceuticals, Inc., Viridian Therapeutics or Inc. is the better investment when it comes to sustainable growth.

Recursion Pharmaceuticals, Inc., Viridian Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Recursion Pharmaceuticals, Inc.	RXRX	D
Viridian Therapeutics, Inc.	VRDN	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Recursion Pharmaceuticals, Inc. has a Momentum Score of 24, which is Weak. Viridian Therapeutics, Inc. has a Momentum Score of 91, which is Very Strong.

The Momentum Grade Winner: Viridian Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Viridian Therapeutics, Inc. is considered to have stronger momentum compared to Recursion Pharmaceuticals, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Viridian Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Recursion Pharmaceuticals, Inc., Viridian Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Recursion Pharmaceuticals, Inc.	RXRX	D
Viridian Therapeutics, Inc.	VRDN	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Recursion Pharmaceuticals, Inc. has a Earnings Estimate Score of 29, which is Negative. Viridian Therapeutics, Inc. has a Earnings Estimate Score of 64, which is Positive.

The Earnings Estimate Revisions Grade Winner: Viridian Therapeutics, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Viridian Therapeutics, Inc. has a better Earnings Estimate Revisions Grade than Recursion Pharmaceuticals, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Viridian Therapeutics, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Recursion Pharmaceuticals, Inc., Viridian Therapeutics and Inc. Grades

In addition to Estimate Revisions, Momentum and Growth, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Recursion Pharmaceuticals, Inc., Viridian Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Recursion Pharmaceuticals, Inc., Viridian Therapeutics or Inc. Stock?

Overall, Recursion Pharmaceuticals, Inc. stock has a Growth Score of 28, Momentum Score of 24 and Estimate Revisions Score of 29.

Viridian Therapeutics, Inc. stock has a Growth Score of 1, Momentum Score of 91 and Estimate Revisions Score of 64.

Comparing Recursion Pharmaceuticals, Inc., Viridian Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.